Clinical Trial

Americord Releases Cord Blood Stem Cells for Treatment of Motor Neuron Disease

SOMERSET, NJ / ACCESSWIRE / February 23, 2024 / Americord, a leading private stem cell bank, announced the release of…

7 months ago

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of…

7 months ago

Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance

SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided…

7 months ago

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage…

7 months ago

FDA Moves Ahead With MMJ Cannabis Drug Application

"MMJ International Holdings has manufactured a botanical extract in a final dose form gel cap and will investigate its novel…

7 months ago

Establishment Labs Announces Amended Credit Facility with Oaktree

- Amendment of commercial and regulatory milestones for $50 million of additional non-dilutive capital to support launch of Motiva Implants®…

7 months ago

Establishment Labs Announces Amended Credit Facility with Oaktree

- Amendment of commercial and regulatory milestones for $50 million of additional non-dilutive capital to support launch of Motiva Implants®…

7 months ago

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates

Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year…

7 months ago

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”),…

7 months ago

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 (GLOBE…

7 months ago